Literature DB >> 25900820

The synthesized vectorcardiogram resembles the measured vectorcardiogram in patients with dyssynchronous heart failure.

Elien B Engels1, Salih Alshehri1, Caroline J M van Deursen2, Liliane Wecke3, Lennart Bergfeldt4, Kevin Vernooy5, Frits W Prinzen6.   

Abstract

BACKGROUND: The use of vectorcardiography (VCG) has regained interest, however, original Frank-VCG equipment is rare. This study compares the measured VCGs with those synthesized from the 12-lead electrocardiogram (ECG) in patients with heart failure and conduction abnormalities, who are candidate for cardiac resynchronization therapy (CRT).
METHODS: In 92 CRT candidates, Frank-VCG and 12-lead ECG were recorded before CRT implantation. The ECG was converted to a VCG using the Kors method (Kors-VCG) and the two methods were compared using correlation and Bland-Altman analyses.
RESULTS: Variables calculated from the Frank- and Kors-VCG showed correlation coefficients between 0.77 and 0.90. There was a significant but small underestimation by the Kors-VCG method, relative bias ranging from -1.9% ± 4.6% (QRS-T angle) to -9.4% ± 20.8% (T area).
CONCLUSION: The present study shows that it is justified to use Kors-VCG calculations for VCG analysis, which enables retrospective VCG analysis of previously recorded ECGs in studies related to CRT.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac resynchronization therapy; Electrical dyssynchrony; Kors method; Vectorcardiography

Mesh:

Year:  2015        PMID: 25900820     DOI: 10.1016/j.jelectrocard.2015.04.001

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  7 in total

1.  Vectorcardiographic QRS area is associated with long-term outcome after cardiac resynchronization therapy.

Authors:  Kasper Emerek; Daniel J Friedman; Peter Lyngø Sørensen; Steen Møller Hansen; Jacob Moesgaard Larsen; Niels Risum; Anna Margrethe Thøgersen; Claus Graff; Joseph Kisslo; Peter Søgaard; Brett D Atwater
Journal:  Heart Rhythm       Date:  2018-08-28       Impact factor: 6.343

Review 2.  Toward Sex-Specific Guidelines for Cardiac Resynchronization Therapy?

Authors:  Robbert Zusterzeel; Kimberly A Selzman; William E Sanders; Kathryn M O'Callaghan; Daniel A Caños; Kevin Vernooy; Frits W Prinzen; Anton P M Gorgels; David G Strauss
Journal:  J Cardiovasc Transl Res       Date:  2015-12-10       Impact factor: 4.132

3.  A single-centre prospective evaluation of left bundle branch area pacemaker implantation characteristics.

Authors:  L I B Heckman; J G L M Luermans; M Jastrzębski; B Weijs; A M W Van Stipdonk; S Westra; D den Uijl; D Linz; M Mafi-Rad; F W Prinzen; K Vernooy
Journal:  Neth Heart J       Date:  2022-04-05       Impact factor: 2.854

Review 4.  Why QRS Duration Should Be Replaced by Better Measures of Electrical Activation to Improve Patient Selection for Cardiac Resynchronization Therapy.

Authors:  Elien B Engels; Masih Mafi-Rad; Antonius M W van Stipdonk; Kevin Vernooy; Frits W Prinzen
Journal:  J Cardiovasc Transl Res       Date:  2016-05-26       Impact factor: 4.132

5.  Vectorcardiographic QRS area as a predictor of response to cardiac resynchronization therapy.

Authors:  Mohammed A Ghossein; Antonius Mw van Stipdonk; Frits W Prinzen; Kevin Vernooy
Journal:  J Geriatr Cardiol       Date:  2022-01-28       Impact factor: 3.327

6.  Baseline QRS Area and Reduction in QRS Area Are Associated with Lower Mortality and Risk of Heart Failure Hospitalization after Cardiac Resynchronization Therapy.

Authors:  Sofia Marinko; Pyotr G Platonov; Jonas Carlson; Rasmus Borgquist
Journal:  Cardiology       Date:  2022-01-24       Impact factor: 2.342

7.  Synchronization of repolarization after cardiac resynchronization therapy: A combined clinical and modeling study.

Authors:  Nienke J Verzaal; Caroline J M van Deursen; Simone Pezzuto; Liliane Wecke; Wouter M van Everdingen; Kevin Vernooy; Tammo Delhaas; Angelo Auricchio; Frits W Prinzen
Journal:  J Cardiovasc Electrophysiol       Date:  2022-06-11       Impact factor: 2.942

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.